CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Michelson Diagnostics, Ltd. in a Series D financing raising £2,500,000. The round was led by Smith & Nephew and Kent County Council and supported by Octopus Investments and several individual angel investors.
Michelson Diagnostics (Kent, United Kingdom) develops, manufactures and markets the VivoSight multi-beam Optical Coherence Tomography (‘OCT’) scanner; a point-of-care, real-time tissue imaging device. The patented technology, which has CE/TGA regulatory clearance and FDA 510(k) approval in the United States, provides clinicians with continuous images of the epidermis and superficial dermis of the skin that can be interpreted by a medical professional. Given the unprecedented image resolution and image quality, VivoSight OCT has many potential clinical applications beyond the initial focus in dermatology. The Company’s vision is for the VivoSight OCT system to become the standard-of-care for the non-invasive diagnosis and treatment monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body. Michelson Diagnostics currently generates revenues from the first commercial application of VivoSight, in the diagnosis of non-melanoma skin cancer (NMSC). For more information visit www.michelsondiagnostics.com or www.vivosight.com.
CATALYSIS Advises Life Science Innovators. Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK